Compass Pathways Closes Enrollment For Phase IIb Psilocybin Clinical Trial
Compass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the latest status of its ongoing
Read more
Compass Pathways
Psychedelics: The Eight Capital Primer
Eight Capital recently produced a primer on the psychedelic sector saying that the companies are “poised to fill a growing
Read more
David Nutt: Amanita Muscaria Due For More Research – The Daily Dive
Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt, a highly experienced neuropsychopharmacologist, the
Read more
Compass Pathways Leader Of Investment Climate For Psychedelic Plays – The Daily Dive feat Jeff Stevens
Today on the Daily Dive, Jeff Stevens returns to the show to sit down with host Cassandra Leah to discuss
Read more
Psychedelics & The Need For Digital Therapeutic Solutions In Treating Mental Health
In terms of investment dollar inflows, one of the largest focuses of 2020 has arguably been that of the growing
Read more
Andrew Left’s Citron Research Places $100 Price Target On Compass Pathways
Andrew Left of Citron Research today released a research paper on Compass Pathways (NASDAQ: CMPS), giving it a long term
Read more
Compass Pathways, Psilocybin Research Firm, Files For Nasdaq IPO
It appears that some authenticity and validation might be coming to the psychedelics space. Compass Pathways, a UK startup focused
Read more